The Outcome of Haplo-Identical Transplantation in Patients with Relapsed Multiple Myeloma: An EBMT/CIBMTR Report
Despite tremendous strides in the treatment of multiple myeloma (MM), the disease remains incurable and is defined by multiple series of responses and relapses. In the relapsed/refractory setting, outcomes for patients may be particularly discouraging. Moreover, patients with adverse cytogenetics and other high-risk features may experience particularly short progression-free survival (PFS) and inferior survival rates.[1] (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - September 20, 2018 Category: Hematology Authors: Firoozeh Sahebi, Laurent Garderet, Abraham S Kanate, Diderik-Jan Eikema, Nina Simone Knelange, Omar F D ávila Alvelo, Yener Koc, Didier Blaise, Qaiser Bashir, José M Moraleda, Peter Dreger, James F. Sanchez, Stefan Ciurea, Harry Schouten, Nirav N Shah, Source Type: research

KIR genotyping data of more than three million individuals are available for global unrelated stem cell donor searches (Comment to: Weisdorf D, Cooley S, Wang T, et al. KIR donor selection: feasibility in identifying better donors. Biol Blood Marrow Transplant. 2018; doi: 10.1016/j.bbmt.2018.08.022.)
Weisdorf et al. [1] report on the feasibility of optimized unrelated stem cell donor selection by donor KIR genotyping during ongoing donor searches. They identify core issues of this process – including participation of transplant centers, number of requested donors per search, donor availability for KIR genotyping, and coverage of KIR genotyping costs – and conclude that pre-search donor KIR genotyping would “accelerate the search process and provide useful data to provide the be st donors quickly”. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - September 20, 2018 Category: Hematology Authors: Alexander H. Schmidt, Vinzenz Lange, Jan A. Hofmann, Johannes Schetelig, Julia Pingel Source Type: research

High Dose Chemotherapy with Early Autologous Stem Cell Transplantation Compared to Standard Dose Chemotherapy or Delayed Transplantation in Patients with Newly Diagnosed Multiple Myeloma: A Systematic Review and Meta-analysis
High dose therapy (HDT) with autologous stem cell rescue (SCT) following induction therapy has been the standard treatment for multiple myeloma (MM) in transplant-eligible patients since the 1990s. When this approach was studied in the 1980s, HDT with SCT led to higher rates of complete response which translated into prolonged duration of remission 1,2. HDT with SCT can be in the form of a single course of HDT followed by stem cell rescue or a tandem approach where 2 planned SCTs are conducted serially. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - September 20, 2018 Category: Hematology Authors: Tania Jain, Mohamad Bassam Sonbol, Belal Firwana, Kantha R. Kolla, Diana Almader-Douglas, Jeanne Palmer, Rafael Fonseca Source Type: research

Impact of obesity on clinical outcomes of elderly patients undergoing allogeneic hematopoietic cell transplant for myeloid malignancies
Myeloid malignancies such as acute myelogenous leukemia (AML) and myelodysplastic syndrome (MDS), are potentially life-threatening diseases of the elderly, occurring mostly in the seventh to eighth decades of life 1,2. The general approach to treatment is a form of induction chemotherapy followed by consideration of allogeneic hematopoietic cell transplant (allo-HCT) as consolidation therapy in select patients felt to have high-risk disease and be fit for transplantation. Historically, allo-HCT was reserved for young patients with an acceptable performance status but with the adaptation of reduced intensity and non-myeloab...
Source: Biology of Blood and Marrow Transplantation - September 19, 2018 Category: Hematology Authors: Ensi Voshtina, Aniko Szabo, Mehdi Hamadani, Timothy S. Fenske, Anita D'Souza, Saurabh Chhabra, Wael Saber, William R. Drobyski, Parameswaran Hari, Nirav N. Shah Source Type: research

Double negative T cells levels correlate with chronic graft-versus-host disease severity
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) can eradicate several blood cancers otherwise incurable by chemotherapy alone, in large part due to the graft-versus-tumour effect1. Despite indisputable successes due to the graft-versus-tumour effect, the efficacy of allo-HSCT is hampered by cancer recurrence and the development of graft-versus-host disease (GVHD)2, 3. Notably, reduced intensity conditioning in lieu of myeloablative conditioning has improved patient survival following allo-HSCT by attenuating the acute toxic effects4. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - September 19, 2018 Category: Hematology Authors: Erin E. Hillhouse, St éphanie Thiant, Moutuaata M. Moutuou, Félix Lombard-Vadnais, Rachel Parat, Jean-Sébastien Delisle, Imran Ahmad, Denis-Claude Roy, Martin Guimond, Jean Roy, Sylvie Lesage Source Type: research

Ten Things to Know About Primary Mediastinal B-cell Lymphoma
Comments (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - September 19, 2018 Category: Hematology Authors: Irit Avivi Source Type: research

Unique Challenges of Hematopoietic Cell Transplantation in Adolescent and Young Adults with Hematologic Malignancies
Adolescents and young adults (AYA) with cancer are a distinct group of patients at the interface between pediatric and adult services, and are designated as a vulnerable population by National Cancer Institute. Though the definition of AYA differs from country to country, the most commonly accepted range is 15-39 years of age.1, 2 Hematological malignancies comprise approximately 10-15% of all AYA cancers, and management of hematologic malignancies including hematopoietic cell transplantation (HCT) in AYAs is complex. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - September 19, 2018 Category: Hematology Authors: Parinda A. Mehta, Seth J Rotz, Navneet S Majhail Source Type: research

The Dilemma of Conditioning Intensity: When Does Myeloablative Conditioning Improve Outcomes for Allogeneic Hematopoietic Cell Transplantation
Allogeneic hematopoietic cell transplantation (HCT) is an established curative therapy for patients with high risk acute myelogenous leukemia (AML) and myelodysplastic syndrome (MDS). The success of allogeneic HCT is highly dependent on multiple patient, disease and transplant related factors [1-3]. Historically, allogeneic HCT was based on high intensity preparative regimens with an intent to achieve marrow aplasia. As the role of graft versus leukemia benefit became more evident in curing myeloid malignancies, several reduced intensity conditioning (RIC) regimens were studied and showed sustained engraftment, low regimen...
Source: Biology of Blood and Marrow Transplantation - September 19, 2018 Category: Hematology Authors: Melhem M. Solh, Scott R. Solomon, Lawrence E. Morris, Xu Zhang, H. Kent Holland, Asad Bashey Source Type: research

Collection, cryostorage, transplantation and disposal of hematopoietic stem cell products
High-dose chemotherapy (HD-CHT) followed by autologous blood stem cell transplantation (ABSCT) represents a standard therapy for a variety of malignant and non-malignant diseases, including leukemia, lymphoid malignancies, multiple myeloma (MM), solid tumors (e.g., germ cell tumors, sarcoma), amyloid light chain (AL) amyloidosis and autoimmune disorders.1-5 Peripheral blood stem cells (PBSCs) have become the most widely used source for hematopoietic stem cells in this setting.6,7 Considering the difficulties of collecting an additional PBSC graft after the initial myeloablative HD-CHT and ABSCT, many centers routinely coll...
Source: Biology of Blood and Marrow Transplantation - September 19, 2018 Category: Hematology Authors: Katharina Kriegsmann, Maurizio Wack, Petra Pavel, Anita Schmitt, Mark Kriegsmann, Thomas Bruckner, Carsten M üller-Tidow, Patrick Wuchter Source Type: research

Characterization of late acute and chronic graft-versus-host disease according to the 2014 NIH consensus criteria in Japanese patients
Introduction (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - September 19, 2018 Category: Hematology Authors: Reiko Ito, Yoshihiro Inamoto, Yoshitaka Inoue, Ayumu Ito, Takashi Tanaka, Shigeo Fuji, Keiji Okinaka, Saiko Kurosawa, Sung-Won Kim, Takuya Yamashita, Takahiro Fukuda Source Type: research

Cognitive Function and Quality of Life in Vorinostat-Treated Patients Following Matched Unrelated Donor Myeloablative Conditioning Hematopoietic Cell Transplant
Emerging data suggest that adult recipients of hematopoietic cell transplants (HCT) are at risk of cognitive decline, which can be subtle and transitory, or may extend beyond one and five years post-HCT. [1-3] While autologous HCT has been associated with little cognitive decline, allogeneic HCT has been associated with acute cognitive decline that persists over time or is delayed, depending on whether it is in the myeloablative or reduced intensity conditioning setting, respectively. [4] Well-recognized factors contributing to cognitive decline include the neurotoxic effects of chemotherapy, radiation (e.g., total body ir...
Source: Biology of Blood and Marrow Transplantation - September 19, 2018 Category: Hematology Authors: Flora Hoodin, Leah LaLonde, Josh Errickson, Kristen Votruba, Rachel Kentor, Erin Gatza, Pavan Reddy, Sung Won Choi Source Type: research

Outcomes After Second Hematopoietic Cell Transplant for Children and Young Adults with Relapsed Acute Leukemia
For children with acute myeloid (AML) or lymphoblastic (ALL) leukemia who relapse after their first allogeneic hematopoietic cell transplant (HCT), treatment options are limited. Although a second HCT is an option, its outcome is dependent on morbidities experienced from initial and salvage chemotherapies, as well as the first HCT, performance status, interval between first HCT and relapse and disease status at second HCT.1-8 These reports have largely focused on adults with acute and chronic leukemia, with only modest inclusion of children. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - September 19, 2018 Category: Hematology Authors: Troy C. Lund, Kwang Woo Ahn, Heather R. Tecca, Megan V. Hilgers, Hisham Abdel-Azim, Allistair Abraham, Miguel Angel Diaz, Sherif M. Badawy, Larisa Broglie, Valerie Brown, Christopher C. Dvorak, Marta Gonzalez-Vicent, Hasan Hashem, Robert J. Hayashi, David Source Type: research

Evaluation of a Test Dose Strategy for Pharmacokinetically-guided Busulfan Dosing for Hematopoietic Stem Cell Transplant
Busulfan has been used as a component of conditioning regimens in hematopoietic stem cell transplant (HCT) since the 1950 ’s. Since then, formulations and dosing regimens have evolved.1 Limitations to the use of oral busulfan include inter- and intrapatient variability in exposure, the need for frequent dosing, and increased first-pass metabolism, potentially increasing the rate of sinusoidal obstruction syndrome (SO S) and other toxicities.2-4 Intravenous (IV) busulfan improves the pharmacokinetic (PK) variability, can be administered once daily, and reduces the toxicity profile. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - September 19, 2018 Category: Hematology Authors: Jessica Michaud Davis, Anastasia Ivanova, Yunro Chung, J. Ryan Shaw, Kamakshi Rao, Jonathan PtachcinskidAndrew Sharf, Jonathan Serody, Paul Armistead, William A Wood, James Coghill, Katarzyna Jamieson, Benjamin G Vincent, Marcie Riches, Thomas Shea, Mauri Source Type: research

Turn off the Tap! The Need for Induction Therapy for AL Amyloidosis Before Transplant
AL amyloidosis is a plasma cell disorder characterized by an excess proliferation of light chains yielding characteristic deposits in critical organs such as the kidney and the heart. Similar to myeloma, treatment is directed at the light chain producing plasma cells with novel therapies and hematopoietic stem cell transplant. The morbidity and mortality of AL amyloid stems from severe organ dysfunction – and most traditional therapies are not able to extricate these damaging deposits from the cardiac, renal or neurological system which they have corrupted. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - September 19, 2018 Category: Hematology Authors: Joseph Mikhael Source Type: research

Outcomes of patients with recurrent and refractory lymphoma undergoing allogeneic hematopoietic cell transplantation with BEAM conditioning and sirolimus and tacrolimus based GVHD prophylaxis
Autologous stem cell transplantation (ASCT) with high dose conditioning is the current standard of care for patients with relapsed non-Hodgkin's lymphoma (NHL) or Hodgkin's lymphoma (HL).1,2 Outcomes of a large retrospective study done by the Center for Blood and Marrow Transplant Research (CIBMTR), comparing the impact of several commonly used high-dose therapy regimens in patients with NHL and HL demonstrated that among patients with HL, BEAM (BCNU, etoposide, cytarabine and melphalan) regimen was associated with better survival compared to all other regimens, and indicated that there is variability in toxicity and disea...
Source: Biology of Blood and Marrow Transplantation - September 15, 2018 Category: Hematology Authors: Amandeep Salhotra, Matthew Mei, Tracey Stiller, Sally Mokhtari, Alex F. Herrera, Robert Chen, Leslie Popplewell, Jasmine Zain, Haris Ali, Karamjeet Sandhu, Elizabeth Budde, Auayporn Nademanee, Stephen J. Forman, Ryotaro Nakamura Source Type: research

The impact of advanced patient age on mortality after allogeneic hematopoietic Cell Transplantation for Non-Hodgkin's Lymphoma: A retrospective study by the EBMT Lymphoma Working Party
More than 60% of patients with non-Hodgkin lymphoma (NHL) are over 60 years old at presentation. The purpose of this study was to compare the potential risks and benefits of allogeneic HSCT in elderly patients with NHL with younger patients in a large sample taking also into account comorbidity information. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - September 13, 2018 Category: Hematology Authors: Charalampia Kyriakou, Ariane Boumendil, Herve Finel, NNNorbert Schmitz, Niels Smedegaard Andersen, Didier Blaise, Patrice Chevallier, Paul Browne, Ram Malladi, Dietger Niederwieser, Antonio Pagliuca, Frank Kroschinsky, Silvia Montoto, Peter Dreger, EBMT Source Type: research

Mobilization of Hematopoietic Progenitor Cells for Autologous Transplantation Using Pegfilgrastim and Plerixafor: Efficacy and Cost Implications
Autologous hematopoietic cell transplant (auto-HCT) is a mainstay treatment for hematologic malignancies such as multiple myeloma and lymphomas. Peripheral blood hematopoietic progenitor cells (PB-HPC) offer a faster hematopoietic recovery than HPC from bone marrow, making it the most common source of cells for auto-HCTs [1,2]. Three general approaches to mobilize PB-HPC are available: myeloid growth factors with or without the CXCR4 antagonist, plerixafor, and chemotherapy plus growth factors. Chemotherapy mobilization has been shown to produce similar failure rates with increased cost and toxicity compared to myeloid gro...
Source: Biology of Blood and Marrow Transplantation - September 13, 2018 Category: Hematology Authors: Nicole L Watts, Marisa B. Marques, Daniel B Peavey, Racquel Innis-Shelton, Ayman Saad, Antonio Di Stasi, Donna Salzman, Lawrence S Lamb, Luciano J Costa Source Type: research

The Anatomic Distribution of Skin Involvement in Patients with Incident Chronic Graft-versus-Host Disease
Skin is the most common area of chronic graft-versus-host disease (cGVHD) involvement, and classic skin features of cGVHD are sufficient to establish the diagnosis.1 However, little is known about the distribution of cutaneous cGVHD. There are limited studies detailing anatomic distribution of cGVHD skin involvement, while incidence and risk factors are well-described.2,3 Understanding the distribution and symmetry of cGVHD is essential to establish target or sentinel areas (if any) on which to focus monitoring efforts in future studies. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - September 13, 2018 Category: Hematology Authors: Jocelyn S. Gandelman, John Zic, Anna K. Dewan, Stephanie J. Lee, Mary Flowers, Corey Cutler, Joseph Pidala, Heidi Chen, Madan H. Jagasia, Eric R. Tkaczyk Tags: Regular Article Source Type: research

The importance of A, B, Cs! Airways and Breathing matter for survival after HSCT
Pulmonary compromise has been shown to significantly contribute to non-relapse mortality after hematopoietic stem cell transplantation (or HSCT).1-4 The etiology of these pulmonary complications includes intrapulmonary causes of fibrosis and toxicities from treatment regimens or infections (restrictive lung disease), graft-versus-host disease or bronchiolitis obliterans syndrome (obstructive lung disease), and vascular abnormalities (e.g. pulmonary hypertension), as well as extrapulmonary causes such as weakness or sclerodermatous GVHD. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - September 12, 2018 Category: Hematology Authors: Kirsten Williams Source Type: research

Ruxolitinib Therapy Followed by Reduced Intensity Conditioning for Hematopoietic Cell Transplantation for Myelofibrosis – Myeloproliferative Disorders Research Consortium 114 study
Myelofibrosis (MF) is a chronic haematological malignancy characterized by variable degrees of anemia and thrombocytopenia, marrow fibrosis, extramedullary hematopoiesis, splenomegaly, cytokine driven inflammatory symptoms, and an increased risk of transformation to acute myeloid leukemia (AML) and reduced life expectancy. Dysregulation of the JAK-STAT pathway is a hallmark of MF irrespective of phenotypic driver mutations in JAK2, CALR and MPL genes. The use of JAK 1/2 inhibitors (JAKi) in MF patients have led to control of disease related symptoms, resulting in approval of ruxolitinib. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - September 8, 2018 Category: Hematology Authors: Vikas Gupta, Heidi E. Kosiorek, Adam Mead, Rebecca B Klisovic, John P. Galvin, Dmitriy Berenzon, Abdulraheem Yacoub, Auro Viswabandya, Ruben A. Mesa, Judith Goldberg, Leah Price, Mohamed E Salama, Rona Singer Weinberg, Raajit Rampal, Noushin Farnoud, Amyl Source Type: research

Cord-Haplo Identical Non-in-vitro T-cell-depletion Allogeneic Hematopoietic Stem Cell Transplantation Reduces Relapse for Refractory Acute Leukemia
Refractory acute leukemia (AL) has a dismal prognosis and represents a tremendous therapeutic challenge. Conventional allogeneic hematopoietic stem cell transplantation (allo-HSCT) only yields long-term survival rates in 7 –24% of patients with refractory acute lymphocytic leukemia and 10–40% of those with late-stage acute myeloid leukemia (AML) [1-6]. Although several recent studies of allo-HSCT using 2 grafts (i.e., double-umbilical cord blood [UCB] transplantation [dUCBT]) and haplo-cord HSCT have shown an enha nced graft-versus-leukemia (GVL) effect along with a graft-versus-graft (GVG) response [4, 7-17], ...
Source: Biology of Blood and Marrow Transplantation - September 8, 2018 Category: Hematology Authors: Jingbo Wang, Zheng Wang, Wei Wei, Weijie Zhang, Tao Zhang, Haoyu Cheng, Xinhong Fei, Yuming Yin, Jiangying Gu, Lei Yuan Source Type: research

Ruxolitinib as Salvage Therapy for Chronic Graft-versus-Host Disease
Chronic graft-versus-host disease (cGvHD) remains a major barrier to a successful hematopoietic stem cell transplantation (HSCT) associated with lower quality of life (QOL) and significant morbidity and mortality.1 Corticosteroids are widely accepted as first-line therapy and most often recommended by expert consensus groups.2 Unfortunately, a significant percentage of cGvHD patients do not improve with steroids, and there is no widely agreed-upon second-line agent to treat these patients.3 (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - September 7, 2018 Category: Hematology Authors: Badri Modi, Michael Hernandez-Henderson, Dongyun Yang, Jeremy Klein, Sanjeet Dadwal, Erin Kopp, Karen Huelsman, Sally Mokhtari, Haris Ali, Monzr M. Al Malki, Ricardo Spielberger, Amandeep Salhotra, Pablo Parker, Stephen Forman, Ryotaro Nakamura Source Type: research

Significant Nationwide Variability exists in the Costs and in Hospital Mortality Rates in Autologous Stem Cell Transplant for Multiple Myeloma: An Analysis of the Nationwide Inpatient Sample (NIS) Database
Multiple myeloma (MM) is a rare cancer with an annual incidence of 30,000, comprising 1% of all cancer in the United States [1]. Recent advances in MM treatment and supportive care have improved overall survival (OS) outcomes for patients; however, the causes of variation in survival outcomes among treatment centers have not been extensively evaluated. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - September 6, 2018 Category: Hematology Authors: Yuzhou Liu, Hedong Han, Gunjan Shah, Sergio Giralt, C. Ola Landgren, Jia He, Alexander M. Lesokhin Source Type: research

Significant Risk of Graft-versus-Host Disease with Exposure to Checkpoint Inhibitors Before and After Allogeneic transplantation
The use of allogeneic hematopoietic stem cell transplantation (allo-HSCT) in treating aggressive hematological malignancies has potential for graft versus tumor (GVT) effect on one hand, and risk of graft versus host disease (GVHD) on the other. Despite the use of intensive conditioning followed by allo-HSCT, primary disease relapse remains one of the leading causes of death 1, 2. A summary report published by the Center for International Blood and Marrow Transplant (CIBMTR) shows that patients who received transplants from matched unrelated donors (MUD) and HLA matched siblings (MRD) have relapse rates of 30% and 40% resp...
Source: Biology of Blood and Marrow Transplantation - September 5, 2018 Category: Hematology Authors: Awais Ijaz, Ali Younas Khan, Saad Ullah Malik, Warda Faridi, Muhammad Asad Fraz, Muhammad Usman, Muhammad Junaid Tariq, Seren Durer, Ceren Durer, Atlantis Russ, Nadia Nunes Cavalcante Parr, Zeeshan Baig, FNU Sagar, Zeeshan Ali, Ali McBride, Faiz Anwer Tags: Rapid communication Source Type: research

The impact of a hematopoietic stem cell transplantation on dental development
Hematopoietic stem cell transplantation (HSCT) is currently the only treatment with curative potential for various malignant and nonmalignant disorders [1]. In preparation for HSCT, patients are conditioned with chemotherapy, irradiation, and /or serotherapy to eliminate residual malignant cells, prevent acute and chronic graft versus host disease and facilitate engraftment. Chemotherapy based preparative regimens often contain alkylating drugs such as cyclophosphamide or busulfan [1, 2]. Total body irradiation (TBI) based preparative regimens are used exclusively in children older than 3 years and only for malignant disor...
Source: Biology of Blood and Marrow Transplantation - September 4, 2018 Category: Hematology Authors: Laure Ruyssinck, Kaat Toulouse, Victoria Bordon Cueto de Braem, Rita Cauwels, Catharina Dhooge Source Type: research

Allogeneic Hematopoietic Cell Transplantation in Patients aged 50 years or older with Severe Aplastic Anemia
Treatment algorithms for severe aplastic anemia (SAA) are not well characterised for older patients. For older patients, treatment decisions are based not only on disease factors but also on their health and functional ability, in order to reduce the risk of treatment-related toxicity that may contribute to morbidity and mortality 1. For these reasons, HCT in older patients with SAA is usually only considered as second line treatment 2. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - September 4, 2018 Category: Hematology Authors: C. Rice, D.J. Eikema, J.C.W. Marsh, C. Knol, K. Hebert, H. Putter, E. Peterson, H.-J. Deeg, C.J.M. Halkes, J. Pidala, P. Anderlini, J. Tischer, N. Kroger, A. McDonald, J.H. Antin, N.P.M. Schaap, M. Hallek, H. Einsele, V. Mathews, N. Kapoor, J.J. Boelens, Source Type: research

HLA mismatched donors in patients with myelodysplastic syndrome: an EBMT registry analysis
Allogeneic Hematopoietic stem cell transplant (HSCT) remains the only curative treatment in patients with myelodysplastic syndrome (MDS). The reduction in transplant related mortality in recent years has expanded the applicability of transplant to older patients and those with co-morbidities. This is particularly relevant for patients with MDS who have a median age at diagnosis of 72 years. The introduction of reduced intensity regimens (RIC) and the improvement in donor availability has further contributed to an increase transplant numbers globally. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - August 30, 2018 Category: Hematology Authors: Marie Robin, Rapha ël Porcher, Annalisa Ruggeri, Didier Blaise, Christine Wolschke, Linda Koster, Emanuele Angelucci, Friedrich Stölzel, Victoria Potter, Ibrahim Yakoub-Agha, Yener Koc, Fabio Ciceri, Jürgen Finke, Hélène Labussière-Wallet, Maria Jes Source Type: research

Establishment and operation of a third party virus-specific T-cell bank within an allogeneic stem cell transplant program
Viral infections are a major cause of morbidity and mortality following haemopoietic stem cell transplantation (HSCT). The herpesviruses cytomegalovirus (CMV) and Epstein-Barr virus (EBV) are the most frequent viral infections requiring treatment in the 1st year post-allogeneic stem cell transplant. However, standard treatment options are limited with a handful of effective anti-viral drug therapies available, all associated with treatment-limiting toxicities, significant cost, and the potential need for prolonged and/or recurrent treatment often in the inpatient setting. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - August 29, 2018 Category: Hematology Authors: Barbara Withers, Leighton Clancy, Jane Burgess, Renee Simms, Rebecca Brown, Kenneth Micklethwaite, Emily Blyth, David Gottlieb Source Type: research

Allocation to Matched Related or Unrelated Donor Results in Similar Clinical Outcomes without Increased Risk of Failure to Proceed to Transplant among Patients with Acute Myeloid Leukemia: A Retrospective Analysis from the Time of Transplant Approval
Acute myelogenous leukemia (AML) represents the most common indication for allogeneic hematopoietic stem cell transplantation (allo-HSCT) worldwide [1]. Despite major progresses in our understanding of AML biology and the recent arrival of emerging targeted therapies to the field, allo-HSCT remains the first-choice consolidation strategy for fit patients in first remission who are at a high risk of relapse [2,3,4]. Moreover, allo-HSCT is the only therapeutic option resulting in significant long-term survival rates in patients with refractory or relapsed disease [5]. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - August 25, 2018 Category: Hematology Authors: Eduardo Rodr íguez-Arbolí, Francisco José Márquez-Malaver, Nancy Rodríguez-Torres, Teresa Caballero-Velázquez, Virginia Escamilla-Gómez, Cristina Calderón-Cabrera, José Francisco Falantes-González, María Solé-Rodríguez, Patricia García-Ramí Source Type: research

Comparative analysis of calcineurin-inhibitor-based methotrexate and mycophenolate mofetil-containing regimens for prevention of Graft-versus-Host Disease after reduced intensity conditioning allogeneic transplantation
: The combination of calcineurin inhibitor (CNI) such as tacrolimus (TAC) or cyclosporine (CYSP) with methotrexate (MTX) or with mycophenolate mofetil (MMF) has been commonly used for Graft-versus-Host Disease (GVHD) prophylaxis after reduced intensity conditioning (RIC) allogeneic transplantation (alloHCT), but there are limited data comparing efficacy of the two regimens. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - August 25, 2018 Category: Hematology Authors: Saurabh Chhabra, Ying Liu, Michael T. Hemmer, Luciano Costa, Joseph A. Pidala, Daniel R. Couriel, Amin M. Alousi, Navneet S. Majhail, Robert K. Stuart, Dennis Kim, Olle Ringden, Alvaro Urbano-Ispizua, Ayman Saad, Bipin N. Savani, Brenda Cooper, David I. M Source Type: research

Allocation to matched-related or unrelated donor results in similar clinical outcomes without increased risk of failure to proceed to transplant among patients with acute myeloid leukemia: a retrospective analysis from the time of transplant approval
Acute myeloid leukemia (AML) represents the most common indication for allogeneic hematopoietic stem cell transplantation (allo-SCT) worldwide1. Despite major progresses in our understanding of AML biology and the recent arrival of emerging targeted therapies to the field, allo-SCT remains the first-choice consolidation strategy for fit patients in first remission who are at a high risk of relapse2,3,4. Moreover, allo-SCT is the only therapeutic option resulting in significant long-term survival rates in patients with refractory or relapsed disease5. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - August 25, 2018 Category: Hematology Authors: Eduardo Rodr íguez-Arbolí, Francisco José Márquez-Malaver, Nancy Rodríguez-Torres, Teresa Caballero-Velázquez, Virginia Escamilla-Gómez, Cristina Calderón-Cabrera, José Francisco Falantes-González, María Solé-Rodríguez, Patricia García-Ramí Source Type: research

A Pilot, Exploratory, Randomized, Phase 2 Safety Study Evaluating Tumor Cell Mobilization and Apheresis Product Contamination in Patients Treated With Granulocyte Colony Stimulating Factor Alone or Plus Plerixafor
Autologous transplantation of hematopoietic stem cells (HSCs) is a widely used strategy for hematologic and immunologic recovery following high-dose chemotherapy for hematologic malignancies, such as multiple myeloma (MM), non-Hodgkin lymphoma, Hodgkin's disease, and other cancers, including germ-cell tumor and neuroblastoma [1]. After the induction of patients ’ chemotherapy, regardless of whether or not the chemotherapy has been accompanied by cytokine (usually granulocyte colony stimulating factor [G-CSF]) treatment, or after the patient has received treatment with a cytokine alone (such as G-CSF) without associat...
Source: Biology of Blood and Marrow Transplantation - August 24, 2018 Category: Hematology Authors: Hareth Nahi, Marina Celanovic, Qianying Liu, Johan Lund, Valdas Peceliunas Source Type: research

Risk Factors for Parainfluenza Virus Lower Respiratory Tract Disease after Hematopoietic Cell Transplantation
Parainfluenza virus (PIV) is a respiratory virus commonly detected after hematopoietic cell transplantation (HCT) [1-3]. Human PIV has four subtypes, numbered 1 through 4 [4, 5]. PIV type 3 (PIV-3) is the most common subtype and a frequent cause of outbreaks among HCT recipients [6-8]. PIV can progress from upper respiratory tract infection (URTI) to lower respiratory tract disease (LRTD), resulting in mortality as high as 40-50% [3, 9-11]. Identification of risk factors for progression to LRTD and their relative importance is critical in clinical practice and designing clinical trials of novel drugs and immunotherapies. (...
Source: Biology of Blood and Marrow Transplantation - August 24, 2018 Category: Hematology Authors: Sachiko Seo, Hu Xie, Wendy M Leisenring, Jane M Kuypers, Farah T Sahoo, Sonia Goyal, Louise E Kimball, Angela P Campbell, Keith R Jerome, Janet A Englund, Michael Boeckh Source Type: research

KIR Donor Selection: Feasibility in Identifying Better Donors
The preferred unrelated donor is HLA allele-matched [1, 2], young, not previously alloimmunized (through pregnancy or transfusion) [3] and in some, but not all reports, for certain recipients, CMV seronegative [4]. However, other factors have been proposed to identify better donors yielding prompt graft recovery and improved post-transplant outcomes. We previously reported on KIR B haplotype donors and their association with reduced relapse risks and improved disease free-survival (DFS) after unrelated donor (URD) transplants for AML [5,6,7]. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - August 24, 2018 Category: Hematology Authors: Daniel Weisdorf, Sarah Cooley, Tao Wang, Elizabeth Trachtenberg, Michael D. Haagenson, Cynthia Vierra-Green, Stephen Spellman, Ashley Spahn, Jenny Vogel, Hati Kobusingye, Todd Fehninger, Ann Woolfrey, Steven Devine, Maureen Ross, Edmund K. Waller, Ronald Source Type: research

Donor KIR Genotype Impacts on Clinical Outcome after T Cell –Depleted HLA Matched Related Allogeneic Transplantation for High-Risk Pediatric Leukemia Patients
Allogeneic hematopoietic stem cell transplantation (HSCT) has a major role in the treatment of high-risk and relapse acute myelogenous leukemia (AML) and high-risk acute lymphoblastic leukemia, the most important causes of death in children with cancer. [1,2] The best overall survival (OS) and relapse-free survival of this procedure were observed in matched related donors (MRDs), only possible in less than one-third of patients. [3 –5] Recent reports revealed that even with a HLA match, 20% to 40% of patients develop graft-versus-host disease (GVHD). (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - August 23, 2018 Category: Hematology Authors: Adela Escudero, Isabel Mart ínez Romera, Lucía Fernández, Jaime Valentín, Marta González-Vicent, José Luis Vicario, Rosario Madero Jarabo, Miguel Ángel Diaz, Antonio Pérez-Martínez Source Type: research

Donor KIR genotype impacts on clinical outcome after T-cell depleted HLA matched related allogeneic transplantation for high-risk pediatric leukemia patients.
Allogeneic hematopoietic stem cell transplantation (HSCT) has a major role in the treatment of high-risk and relapse acute myeloid leukemia (AML) and high-risk acute lymphoblastic leukemia (ALL), the most important causes of death in children with cancer. [1,2] The best overall and relapse-free survivals of this procedure were observed in matched related donors (MRDs), only possible in less than one-third of patients. [3 –5] Recent reports revealed that even with a human leukocyte antigen (HLA) match, 20%–40% of patients develop graft-versus-host disease (GvHD). (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - August 23, 2018 Category: Hematology Authors: Adela Escudero, Isabel Mart ínez Romera, Lucía Fernández, Jaime Valentín, Marta González-Vicent, José Luis Vicario, Rosario Madero Jarabo, Miguel Ángel Diaz, Antonio Pérez-Martínez Source Type: research

Proinflammatory Cytokine and Adipokine Levels in Adult Unrelated Marrow Donors Are Not Associated with Hematopoietic Cell Transplantation Outcomes
Use of allogeneic hematopoietic cell transplantation (allo-HCT) has increased dramatically over the last 3 decades and is now considered a potentially curative therapy for multiple malignant and nonmalignant diseases [1]. Despite the potential for long-term cure, allo-HCT is associated with significant risks for morbidity and mortality. One of the most frequent complications is graft-versus-host disease (GVHD), which is driven by a cascade of conditioning-induced tissue injury, proinflammatory cytokines, and activation of donor immune cells that recognize host tissue alloantigens, all culminating in tissue destruction by d...
Source: Biology of Blood and Marrow Transplantation - August 22, 2018 Category: Hematology Authors: Lucie M. Turcotte, Tao Wang, Michael T. Hemmer, Stephen R. Spellman, Mukta Arora, Ashley Yingst, Daniel Couriel, Amin Alousi, Joseph Pidala, Jennifer M. Knight, Michael R. Verneris Source Type: research

Use of Non-Cryopreserved Peripheral Blood Stem Cells Is Associated with Adequate Engraftment in Patients with Multiple Myeloma Undergoing an Autologous Transplant
The current standard of care for transplant-eligible patients with multiple myeloma is 4 to 6 cycles of induction therapy with 3 drugs, which induces response in 80% to 90% patients, followed by autologous stem cell transplantation [1]. The process of autologous stem cell transplantation starts with stem cell mobilization (using either cytokine or chemotherapy) and stem cell collection followed by administration of high-dose chemotherapy with melphalan and subsequent reinfusion of the collected stem cells. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - August 22, 2018 Category: Hematology Authors: Uday Kulkarni, Anup J. Devasia, Anu Korula, Fouzia NA, Nisham PN, Yasir J. Samoon, Kavitha M. Lakshmi, Aby Abraham, Alok Srivastava, Vikram Mathews, Biju George Source Type: research

Quantity and Quality Reconstitution of NKG2A+ Natural Killer Cells Are Associated with Graft-versus-Host Disease after Allogeneic Hematopoietic Cell Transplantation
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is an effective treatment strategy for hematologic malignancies [1-6]. However, graft-versus-host disease (GVHD) is a common complication after allo-HSCT [7-10], resulting from the activation, amplification, and secretion of numerous inflammatory factors related to donor alloreactive T cells that damage host tissues and organs, mainly in the gastrointestinal tract, liver, and skin [11]. Notably, natural killer (NK) cells represent the first donor-derived lymphocyte population to recover after allo-HSCT and generally are observed within the first month after all...
Source: Biology of Blood and Marrow Transplantation - August 22, 2018 Category: Hematology Authors: Li-Juan Hu, Xiang-Yu Zhao, Xing-Xing Yu, Meng Lv, Ting-Ting Han, Wei Han, Xiao-Jun Huang Source Type: research

Flow Cytometry Minimal Residual Disease Evolution Pattern Matters for Patients with Multiple Myeloma
Multiple myeloma (MM) is a malignant tumor of plasma cells that infiltrate the bone marrow and secrete monoclonal immunoglobulins, resulting in hypercalcemia, impaired renal function, anemia, bone lesions, and other related complications [1]. With the wide application of autologous stem cell transplant (ASCT) and novel agents including proteasome inhibitors and immunomodulators, both response depth and long-term survival have been significantly improved in MM patients [2]. Minimal residual disease (MRD) but not traditional complete response (CR) may provide the need for a deeper evaluation of the efficacy in patients with ...
Source: Biology of Blood and Marrow Transplantation - August 22, 2018 Category: Hematology Authors: Jingli Gu, Junru Liu, Meilan Chen, Beihui Huang, Juan Li Source Type: research

Pro-inflammatory Cytokine and Adipokine Levels in Adult Unrelated Marrow Donors Are Not Associated with Hematopoietic Cell Transplantation Outcomes
Use of allogeneic hematopoietic cell transplantation (allo-HCT) has increased dramatically over the last 3 decades and is now considered a potentially curative therapy for multiple malignant and non-malignant diseases [1]. Despite the potential for long-term cure, allo-HCT is associated with significant risks for morbidity and mortality. One of the most frequent complications is graft versus host disease (GVHD), which is driven by a cascade of conditioning-induced tissue injury, pro-inflammatory cytokines, and activation of donor immune cells that recognize host tissues allo-antigens, all culminating in tissue destruction ...
Source: Biology of Blood and Marrow Transplantation - August 22, 2018 Category: Hematology Authors: Lucie M. Turcotte, Tao Wang, Michael T. Hemmer, Stephen R. Spellman, Mukta Arora, Ashley Yingst, Daniel Couriel, Amin Alousi, Joseph Pidala, Jennifer M. Knight, Michael R. Verneris Source Type: research

Kinetics and risk factors of relapse after allogeneic stem cell transplantation in children with leukemia: A long-term follow-up single center study
Nowadays, allogeneic hematopoietic stem cell transplantation (allo-HSCT) is considered an established treatment for pediatric patients with high-risk hematological malignancies. Relapse after transplantation still remains the leading cause of death after transplantation1,2 especially in recent years once transplant related mortality has reduced thanks to improved supportive care. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - August 22, 2018 Category: Hematology Authors: Blanca Molina, Marta Gonzalez Vicent, Madrid Blanca Herrero, Madrid Natalia Deltoro, Madrid Julia Ruiz, Madrid Miguel A Diaz, Madrid Antonio Perez Source Type: research

Therapeutic Plasma Exchange Does Not Improve Renal Function in Hematopoietic Stem Cell Transplantation-Associated Thrombotic Microangiopathy: An Institutional Experience
Transplantation-associated thrombotic microangiopathy (TA-TMA) is a complication of hematopoietic stem cell Transplant (HSCT) characterized by microangiopathic hemolytic anemia, thrombocytopenia, and microvascular thrombosis, which can lead to severe end-organ injury. The reported incidence of TA-TMA ranges from 12 – 39%1–3 and mortality can be as high as 90% in severe or untreated cases.3–5 The pathogenesis of TA-TMA is not entirely understood, but is thought to be multifactorial, leading to microvascular endothelial cell injury and formation of microthrombi predominantly in the kidneys, lungs, gastroin ...
Source: Biology of Blood and Marrow Transplantation - August 22, 2018 Category: Hematology Authors: Sarah Sartain, Stacey Shubert, Meng-Fen Wu, Poyyapakam Srivaths, Jun Teruya, Robert Krance, Caridad Martinez Source Type: research

Longitudinal flow cytometry identified “minimal residual disease” (MRD) evolution patterns for predicting the prognosis of patients with transplant-eligible multiple myeloma.
Multiple myeloma (MM) is a malignant tumor of plasma cells that infiltrate the bone marrow and secrete monoclonal immunoglobulins, resulting in hypercalcemia, impaired renal function, anemia, bone lesions and other related complications.1 With the widely application of autologous stem cell transplant (ASCT) and novel agents including proteasome inhibitors (PIs) and immunomodulators (Imids), both the response depth and the long-term survival have been significantly improved in MM patients.2 Minimal residual disease (MRD) but not traditional complete response (CR) may provide the need for a deeper evaluation of the efficacy ...
Source: Biology of Blood and Marrow Transplantation - August 22, 2018 Category: Hematology Authors: Jingli Gu, Junru Liu, Meilan Chen, Beihui Huang, Juan Li Source Type: research

Use of non-cryopreserved peripheral blood stem cells (PBSC) is associated with adequate engraftment in patients with multiple myeloma undergoing an autologous transplant
The current standard of care for transplant eligible patients with multiple myeloma is 4-6 cycles of induction therapy with three drugs which induces response in 80 to 90% patients, followed by autologous stem cell transplantation.1 (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - August 22, 2018 Category: Hematology Authors: Uday Kulkarni, Anup J Devasia, Anu Korula, Fouzia NA, Nisham PN, Yasir J Samoon, Kavitha M Lakshmi, Aby Abraham, Alok Srivastava, Vikram Mathews, Biju George Source Type: research

Quantity and Quality Reconstitution of NKG2A+ NK cells Are Associated with Graft-Versus-Host Disease after Allogeneic Hematopoietic Cell Transplantation
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is an effective treatment strategy for hematological malignancies.1-6 However, graft-versus-host disease (GVHD) is a common complication after allo-HSCT 7-10 resulting from the activation, amplification and secretion of numerous inflammatory factors related to donor alloreactive T cells that damage host tissues and organs, mainly in the gastrointestinal tract, liver and skin.11 Notably, natural killer (NK) cells represent the first donor-derived lymphocyte population to recover after allo-HSCT and generally are observed within the first month after allo-HSCT. (...
Source: Biology of Blood and Marrow Transplantation - August 22, 2018 Category: Hematology Authors: Li-Juan Hu, Xiang-Yu Zhao, Xing-Xing Yu, Meng Lv, Ting-Ting Han, Wei Han, Xiao-Jun Huang Source Type: research

Bone Marrow versus Peripheral Blood from Unrelated Donors for Children and Adolescents with Acute Leukemia
Bone marrow is preferred over peripheral-blood for children and adolescents with acute leukemia undergoing human leukocyte antigen (HLA) matched sibling transplantation.1 Compared to transplantation of bone marrow, higher chronic GVHD and transplant-related mortality after transplantation of peripheral blood resulted in lower leukemia-free and overall survival. A multi-center trial (BMT CTN 0201 NCT#0075816) that randomized patients, including children, to bone marrow or peripheral blood did not show survival differences between the treatment groups although chronic graft-versus-host disease (GVHD) rates were higher after ...
Source: Biology of Blood and Marrow Transplantation - August 22, 2018 Category: Hematology Authors: Daniel A. Keesler, Andrew St. Martin, Carmem Bonfim, Adriana Seber, Mei-Jie Zhang, Mary Eapen Source Type: research

Staging Systems for Newly Diagnosed Myeloma Patients undergoing Autologous Hematopoietic Cell Transplant: The Revised International Staging System shows the most Differentiation between Groups.
The American Cancer Society estimates that about 30,770 new patients will be diagnosed with multiple myeloma (MM) and approximately 12,770 deaths will occur in the USA in 2018.1 Advances in understanding MM biology, drug development and improved supportive care have resulted in the prolongation of life of many patients with this disease but survival is variable, ranging from months to more than 10 years. 2-8 Contemporary prognostic models have been developed since the original Durie-Salmon Staging system published in 1975, which used commonly available clinical parameters including calcium, hemoglobin, bone lesions, creati...
Source: Biology of Blood and Marrow Transplantation - August 22, 2018 Category: Hematology Authors: Emma C. Scott, Parameswaran Hari, Sathish Kumar, Raphael Fraser, Omar Davila, Nina Shah, Robert Peter Gale, Miguel Angel Diaz, Vaibhav Agrawal, Robert F. Cornell, Siddhartha Ganguly, Gorgun Akpek, Cesar Freytes, Shahrukh Hashmi, Ehsan Malek, Rammurti T. K Source Type: research

Defining Competency to Empower Blood and Marrow Transplant and Cellular Immunotherapy Quality Management Professionals in Healthcare
Blood and marrow transplant (BMT) programs worldwide frequently employ a quality management professional who is charged with securing quality and maintaining regulatory requirements. Although many BMT programs employ an individual to oversee quality management, there are no standard definitions of the education, training, and core competencies needed to successfully perform this role. The goal of this article is to propose the required qualifications and responsibilities of the BMT professional who oversees quality management and to elicit discussion to standardize such a role in BMT and cellular immunotherapy programs. (S...
Source: Biology of Blood and Marrow Transplantation - August 20, 2018 Category: Hematology Authors: Ramona Repaczki-Jones, Amanda K. Hrnicek, Amy Heissenbuttel, Steven Devine, Hugo Fernandez, Claudio Anasetti Source Type: research

Defining Competency to Empower BMT and Cellular Immunotherapy Quality Management Professionals in Healthcare
Blood and Marrow Transplant (BMT) Programs worldwide frequently employ a quality management professional who is charged with securing quality and maintaining regulatory requirements. Although many BMT Programs employ an individual to oversee quality management, there are no standard definitions of the education, training, and core competencies needed to successfully perform this role. The goal of this article is to propose the required qualifications and responsibilities of the BMT professional who oversees quality management and to elicit discussion to standardize such a role in BMT and cellular immunotherapy programs. (S...
Source: Biology of Blood and Marrow Transplantation - August 20, 2018 Category: Hematology Authors: Ramona Repaczki-Jones, Amanda K. Hrnicek, Amy Heissenbuttel, Steven Devine, Hugo Fernandez, Claudio Anasetti Source Type: research